Healthcare solutions company Evolent Health (NYSE: EVH) will be announcing earnings results this Tuesday after market close. Here’s what to expect.
Evolent Health beat analysts’ revenue expectations last quarter, reporting revenues of $479.5 million, down 22.8% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and EBITDA guidance for next quarter missing analysts’ expectations significantly.
Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Evolent Health’s revenue to decline 27.5% year on year, a reversal from the 16.3% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Evolent Health’s peers in the healthcare technology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 2.3%, meeting analysts’ expectations, and Tandem Diabetes reported revenues up 15%, topping estimates by 4.9%. Omnicell traded down 20.6% following the results while Tandem Diabetes was up 32.7%.
Read our full analysis of Omnicell’s results here and Tandem Diabetes’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Evolent Health is down 24.8% during the same time and is heading into earnings with an average analyst price target of $8.50 (compared to the current share price of $2.79).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
